| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8448851 | European Journal of Cancer | 2007 | 6 Pages |
Abstract
Melphalan proved to be active in up-front treatment at non-myeloablative doses, and its toxicity was predictable and manageable. The schedule adopted did not interfere with any further intensive chemotherapy or myeloablative treatment in the majority of cases.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
R. Luksch, G. Grignani, F. Fagioli, A. Brach del Prever, M. Podda, S. Aliberti, M. Casanova, A. Prete, G. Hanau, A. Tamburini, P. Allione, A. Tienghi, S. Ferrari, P. Collini, A. Marchianò, L. Gandola, M. Aglietta, E. Madon, F. Fossati-Bellani,